Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5758 | DPDPE |
| Prototypical selective δ-opioid receptor agonist peptide. Inhibits electrically stimulated contraction of mouse vas deferens in vitro (EC50 = 5.2 nM), and is antinociceptive in vivo. | |
| BCC5759 | BMY 14802 hydrochloride |
| Potent sigma receptor antagonist (IC50 = 112 nM) with modest to weak affinity for 5-HT1A and α1 receptors. Antipsychotic following oral administration and acts via indirect modulation of central dopaminergic systems. | |
| BCC5769 | (-)-5'-DMH-CBD |
| Anandamide membrane transport inhibitor (IC50 = 14 μM) that is relatively metabolically stable. Displays some affinity for CB2 receptors but has only weak affinity for CB1 receptors and has no activity at VR1 receptors or FAAH. Anticonvulsive in vivo following systemic administration. | |
| BCC5771 | LY 233053 |
| Competitive NMDA receptor antagonist (IC50 = 7 nM) that displays no affinity for AMPA or kainate receptors at a concentration of 10 μM. Inhibits NMDA-induced neuronal degeneration and protects from NMDA-induced convulsions in neonatal rats. | |
| BCC5773 | 10Z-Hymenialdisine |
| Pan kinase inhibitor (IC50 values are 6, 10, 22, 28, 35, 40, 70, 80, 100, 470, 500, 600, 700 and 700 nM for MEK1, GSK-3β, Cdk1/cyclin B, Cdk5/p25, CK1, Cdk2/cyclin A, Cdk2/cyclin E, ASK-γ, Cdk3/cyclin E, Erk1, PKCγ, Cdk4/cyclin D1, Cdk6/cyclin D2 and PKCα respectively.) Inhibits NF-κB activation and blocks IL-8 production in U937 cells (IC50 values are 1-2 and 0.34-0.48 μM respectively). | |
| BCC5775 | UFP-101 |
| Potent, selective and competitive silent antagonist for the NOP opioid receptor. Binds to NOP with high affinity (pKi = 10.24) and displays > 3000-fold selectivity over δ, μ and κ opioid receptors. Antinociceptive and opposes the action of nociceptin in vivo. | |
| BCC5776 | CTAP |
| Potent and selective μ opioid receptor antagonist (IC50 = 3.5 nM). Displays > 1200-fold selectivity over δ opioid and somatostatin receptors. Brain penetrant and active in vivo. | |
| BCC5778 | [(pF)Phe4]Nociceptin(1-13)NH2 |
| Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo. | |
